Adverse effects of GLP-1 receptor agonists (revision 1)
Old revision·09:00, 30 Jun 2024·ChainCustodyChad
This is an old revision of this page, as it stood at 09:00, 30 Jun 2024, saved by ChainCustodyChad with the summary create article — adverse-effect stub. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Adverse effects of GLP-1 receptor agonists | |
|---|---|
| Most common | Nausea, vomiting, diarrhoea, constipation |
| Timing | Concentrated during escalation |
| Commonest reason for discontinuation | Gastrointestinal intolerance |
| Topic infobox · conventions | |
The adverse effects of GLP-1 receptor agonists are dominated by gastrointestinal events. Nausea, vomiting, diarrhoea and constipation are reported by between a fifth and a half of participants in trials depending on agent and dose, are most frequent during escalation, and diminish with time at a stable dose.[1]
Their mechanism is receptor-level rather than route-level: the same effects occur with an orally administered small-molecule agonist, which argues against a local gastrointestinal irritation explanation. Delayed gastric emptying and area postrema signalling are the proposed contributors.[1]